mellitus appears to be slightly different. That the disease in the tropic differs from that in temperate climate has also been stressed earlier (Hugh-Jones, 1955; Cosnett, 1959; DeZoysa, 1951) . The classical growth-onset type of the disease is relatively rare. In our clinic amongst 329 patients observed during the last one and a half years only five cases of juvenile diabetes were encountered and none of them was below 10 years of age. The extremely low incidence of juvenile diabetes in the tropics was also stressed by DeZoysa, of Ceylon (1951) . However the maturity-onset type of diabetes is quite as common as in Western countries, the only difference being that obesity amongst them is relatively rare, most of them being average weight individuals. Besides these two classical types we have come across diabetes with age of onset between 20 and 40 years differing in some respects from the other groups. Predominantly males, they are usually thin individuals who can remain without insulin for several days with no untoward manifestations. In other words, they are relatively ketoacidosis resistant though they may rarely suffer from this, under extraordinary stressful circumstances. They are also relatively insulin resistant and may require
Paper presented at the World Congress on Diabetes in the Tropics, Bombay, January 20 - 22, 1966. more than 100 units a day for control. This conforms to the description of "J-type" of Hugh-Jones (1955) . Such cases have also been recently described by Tripathy and Kar (1965) from Orissa, India. In our series the incidence of this type has been about 120%. We, however, feel that this does not reflect the true incidence of this type and as its pattern becomes more well known and easily recognisable, the incidence is likely to be more in future. In view of such variations in the pattern of the disease in India, we considered it necessary to assess the efficacy of phenformin hydrochloride timeddisintegration capsules on Indian subjects, since no such study has been made so far.
Materials and Methods
Ninety consecutive patients attending the Diabetic Clinic of the Hospital entered the trial of which 12 were inpatients. There were 68 males and 22 females. The ages ranged between 16 and 73 years. The duration of diabetes ranged from one month to 24 years. Sixteen patients were obese (10 females), 55 were of average weight (12 females) and 19 were underweight of which 7 were emaciated. Fifty-one patients were stable maturityonset type (above 40 years), two were growth-onset juvenile type (16 and 14 years). In thirty-four patients the age of onset was between 20 and 40 years; they were ketoacidosis resistant, though some of them passed a little acetone in urine from time to time. Two patients were adult diabetics developing after 20 years but ketoacidosis prone. In one case diabetes had developed following subtotal pancreatectomy.
Sixty-four of the 90 patients had earlier received one or other forms of antidiabetic drugs with variable results. Amongst them were 12 patients with secondary failures, 4 to tolbutamide, 5 to chlorpropamide and 3 to both.
Each patient received 25 calories/kg. of ideal body weight daily. Correction for sex and obesity was made by deducting 200 calories for the females and 400 calories in the case of obese patients. Additional calories were permitted according to the nature of the activities as follows:-for sedentary workers 400 calories extra, for moderate workers 600 calories extra and for heavy workers 800 -1,000 calories extra. The diet comprised of 200-250 g. of carbohydrate per day, with an allowance of 1 g. of protein/kg. The remainder of the calories were supplied by fat. The levels of pretherapy hyperglycaemia in 86 patients are given in Table 1 . The remaining four patients who were earlier controlled with sulphonylureas had their blood sugar values within normal limits. The level of fasting hyperglycaemia was below 160 mg./100 ml. in only 4 patients and there were two with fasting blood sugar above 400 mg./100 ml.
Timed-disintegration DBI capsules (DBI -TD, 50 mg.) were used orally, 100 mg. to 200 mg. per day in two doses. Changeover from previous antidiabetic drugs to DBI therapy was done after discontinuing the previous therapy for I -2 weeks during which period the patients received only dietetic management. The only exception being in the 4 cases mentioned above where the changeover was instituted without any interval.
There were 21 patients in the series (vide Table 5 ) who had earlier received insulin. In six of them receiving less than 40 units, the changeover was abrupt and no adverse effect was observed. Out of seven other patients receiving more than 40 units the changeover was abrupt in five and here also no adverse effect was seen. The other eight patients were not taking insulin at the commencement of the trial though they had used it most regularly during some period of their diabetic life.
Patients were asked to report to the clinic after a fortnight for check-up of the fasting and post-prandial blood and urine sugar and for recording the side-effects, if any. In patients who did not achieve satisfactory control within the expected time (usually 3 to 4 weeks) the dose was increased gradually up to the maximum of 4 capsules a day. Whoever failed to respond within 4 to 6 weeks was considered as a primary failure; some of these were treated with combination therapy, the change over being prompt allowing no time for the blood sugar to rise.
Patients who were satisfactorily controlled were allowed to continue the same dose and checked at intervals of 4 to 6 weeks. The total period of observation has since extended over 10 months.
Other laboratory investigations done in some of the inpatients included haemogram, liver function tests e.g. SGOT, SGPT, alkaline phosphatase and serum bilirubin, blood cholesterol; plasma carbon dioxide combining power, serum lactic acid and lactic acid in 24 hours' collection of urine.
Results
Response to therapy was graded as 'good,' 'fair' and 'poor' according The good and the fair responses were regarded as successful or satisfactory control.
Results of DBI-TD therapy alone 85 patients received only DBI-TD. The results could be assessed in 66 of them. Of the remaining 19, the drug had to be discontinued in nine due to side effects permitting no time for proper assessment and 10 patients were dropped from the trial due to their irregular attendance to the clinic. The results of therapy in 66 cases are summarised in Table 2 . A satisfactory response was obtained in 74.3 % of the patients. It was observed that certain factors tended to influence the result of DBI-TD therapy and these factors have been analysed below. 1. Age of onset and type of diabetes: (Table 3) . Amongst the 66 subjects who received only DBI-TD the age of onset was above 40 years in 37 individuals. 34 of them (91.8 %) showed satisfactory control. There were 28 patients with age of onset between 20 and 40 years and one patient below 20 years of age. The success rate in the former group was 53.5 % and none in the latter. Thus age of onset was found to modify the result considerably and statistically this was highly significant (P<0.001). Similar was the pattern of response when the chronological age of patients was considered. The solitary case of post-pancreatectomy diabetes did not respond to DBI-TD and was ultimately controlled with 30 units of insulin. 2. Influence of duration of illness: The incidence of success was highest (95.2%) when the duration of the illness was less than one year and the failure rate was very high with the duration of illness more than one year. This was also confirmed statistically (P<0.05). On comparing the success rate in patients with duration of illness less than one year (21 cases) between one to five years (27 cases) and over five years (18 cases) significant difference in the proportion of success (P<0.05) was observed between the first and the last groups.
However closer scrutiny has revealed that this difference was more the reflection of the age of onset rather than of duration per se. 3. Influence of Sex: In females the percentage success was greater (76.4 %) than in males (67.5 %).
More successes were observed in females with duration less than five years and with age of onset more mostly seen amongst underweight patients (Table  6) . Most of these patients who lost some weight during therapy ultimately achieved success; on the other hand most of those who gained weight ended in failure.
Primary Failure Nine subjects failed to respond to therapy primarily. Most of these patients were below 40 years of age with duration of illness over one year and all had received other forms of therapy previously. Five of them were sulphonylurea failure (secondary) cases and one had developed the disease following pancreatectomy.
Side Effects
Most of the side-effects were gastrointestinal. These are listed in Table 7 .
Out of 15 patients who developed side effects, in nine these were severe enough to warrant discontinuation of therapy. At the start of therapy many patients developed slight nausea, weakness and anorexia but these never posed a problem as the patients adjusted themselves to these with the continuation of the drug. Some required help of triflupromazine hydrochloride administered twice or thrice daily before the meals to get over their nausea or vomiting. In others, reduction of the dose caused subsidence of the side effects.
There was no effect on the liver function tests, nor on the haemogram. Serum and urinary lactic acid was estimated in nine cases. The level in the serum was raised in eight patients, the range being 30 to 40 mg./100 ml. Lactic acid in 24 hours urine sample was raised in two subjects only, 312 mg. in one and 320 mg. in the other.
Follow up and secondary failures
The 49 patients who were satisfactorily controlled by DBI-TD alone were followed up for 10 months. The minimum period of follow up was four months. Details are given in Table 8 .
During the period of observation (10 months) two patients escaped control and in one it was most probably due to non-adherence to strict dietetic regime. The previous treatment of these four cases included secondary failures to chlorpropamide in one, to tolbutamide in another and to both in the remaining two. It appeared therefore that successful result was considerably higher in fresh cases (90 %) compared to the previously treated (67.2%)
Discussion
The pattern of diabetes mellitus in India is slightly different from its Western counterpart. While the maturity-onset type is common, the growth-onset juvenile type is rare indeed. The obese diabetics are also infrequent. Moreover a good proportion of the patients belong to the 20 -40 age group but do not fall into any one of the above categories. It was therefore interesting to study the response of phenformin hydrochloride in these subjects. There have been only two Indian reports (Patel, Dhirwani and Deshpande, 1962; Ahuja, Rastogi and Dhar, 1964) on the use of the tablet form of the drug, tried on a small number of patients.
In the present study, comprising an unselected group of 90 patients, phenformin timed-disintegration capsules have been used with a satisfactory response in 74.3 % of the cases; good control in 56.1 % and fair control in 18.2%. The result has been similar to that of Radding,, McHenry, Neely and Lumiss (1962) who obtained a 68% success rate in a series consisting of 68 patients, but inferior to that reported by Weller, Donesa and Morton (1962) of an 88 % success rate amongst 100 patients.
During the period of follow-up which has now been extended up to 10 months only two patients have shown secondary failure. That secondary failure to phenformin is low has been emphasized by earlier workers too (Stowers, 1962) .
Contrary to expectations, the result of the combination therapy with sulphonylurea has not been as good. This was because, unfortunately, five of the seven patients where the combination was attempted happened to be 'secondary failure' cases to one or the other sulphonylurea derivatives and four were primary failures with phenformin. We consider that the combination of sulphonylurea compounds and phenformin should not be attempted without a prior knowledge of the response of the patient to either drug, if disappointment is to be avoided. However in combination with insulin, the result was satisfactory and DBI-TD caused a 57% reduction of the insulin requirement. This confirms earlier observations (Stowers, 1960; Fabrykant and Ashe, 1961) .
It has been reaffirmed recently that several factors tend to modify or influence successful therapy by oral compounds. These are: age of onset, body weight, previous insulin requirement and duration of diabetes. In the present study these factors and the result of DBI therapy on Indian diabetics have been evaluated.
The age of onset of the disease was found to modify the result considerably; the growth-onset type of the disease with age of onset below 20 years did not respond to the therapy, while in the maturityonset type with age of onset above 40 years a successful result was encountered in 91.800. No difference, therefore, is observed in the response of these two types from that reported in Western literature. However a sizeable proportion of the diabetics in the tropics do not conform to the above two classical groups; their age of onset lies between 20-40 years, many are underweight individuals who are relatively less sensitive to insulin but fairly ketoacidosis resistant, except under stressful circumstances. In the present series there were 26 patients who fell in this age group; many amongst them fitted the description of 'J' type of Hugh-Jones (1955) . Recently Tripathy and Kar (1965) have drawn attention to the frequent incidence (22.9%) of this type in Orissa, India. Therapy in such cases is not well defined, in spite of common prevalence of this type in our country. Only 15 of the 26 subjects responded to the DBI-TD therapy (57.6 %). The comparatively poor response in this age group compared to the maturity onset type is striking. This may be due to an inherent resistance to oral therapy of this type as well as to other factors. Detailed analysis showed that the poor response in this group was the result of age of onset rather than of other modifying factors.
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December 1967 The duration of the disease was found to influence the result significantly, the failure rate being 38.3 % with duration more than five years compared to only 9.5 % in duration less than one year. However the effect of duration as already stated is primarily the influence of the age of onset. That response is unrelated to duration has also been found with other sulphonylurea compounds (Katz and Bissel, 1965) . The success rates in the overweight and average-weight patients were 72.7% and 72% respectively in contrast to under-weight individuals in whom it was only 58.3 %. That body weight is a factor which can influence the result of oral therapy has been the impression of earlier workers as well (Waller and others, 1962; Sadow, 1963; Bernhard, 1965 (Stowers, 1960; Walker and Hannah, 1961; Stowers, 1962; Bloom, Newton and Bateman, 1964 With regard to the occurrence of gastrointestinal side effects, DBI-TD was found to be superior to the tablet form of the drug. It occurred in 18.8% of the subjects in this series whereas with the tablet form of the drug a much higher incidence (35%) had been reported earlier (Walker and Hannah, 1961) . We however feel that this incidence is still higher than reported earlier (Weller and others, 1962 
